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Representatives from five international organizations
(International Society of Nephrology, World Heart Federation,
International Diabetes Federation, International
Atherosclerosis Federation, and International Society of
Hypertension) participated in a strategic planning workshop
in December 2005 in Bellagio, Italy sponsored by the
Rockefeller Foundation. There were equal representatives
from developed and developing countries. Global
perspectives on diabetes and cardiovascular and renal
diseases were presented, with special emphasis on China,
India, Latin America, and Africa. The rationale and
effectiveness of preventive measures were discussed. It was
apparent that measures for primary prevention and early
intervention for all the chronic vascular diseases are similar.
The five organizations agreed that an integrated global
approach to chronic vascular diseases is needed. They
resolved to collaborate and work towards an integrated
approach to chronic vascular diseases with the establishment
of a 5-year plan for the prevention and treatment of chronic
vascular diseases, including public advocacy, advising
international and national agencies, and improving
education and the practice of established approaches.
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A landmark meeting funded by the Rockefeller Foundation
was held in Bellagio, Italy in December 2005 to address the
problem of chronic vascular diseases. Organized by John
Dirks, Chair International Society of Nephrology COMGAN
Michael Alderman, President International Society of Hyper-
tension, and Giuseppe Remuzzi Chair ISN COMGAN Research
Committee (Italy), participants included leaders from five
international organizations, namely International Society of
Nephrology (ISN), International Society of Hypertension,
World Heart Federation, International Diabetes Federation,
and International Atherosclerosis Society, and representatives
of WHO and the European Commission. There were 24
participants with 11 from the developing world (Figure 1).
The meeting was structured over 3 days. Session 1 dealt
with ‘A Global Perspective on Cardiovascular–Diabetic–Renal
Disease’. Session 2 dealt with ‘Cardiovascular Disease in the
Developing World: Why the Need for Prevention’. Sessions 3
and 4 examined ‘Prevention of Kidney Disease and Diabetes
in Developing Countries’, and Session 5 addressed ‘A Global
Implementation Plan for Non-Communicable Diseases’.
Session 6, ‘The Challenge of Resources for Dealing with Chronic
Diseases in the 21st Century’, concluded with lively discussion
resulting in a draft consensus statement concerning the global
implementation of this integrated approach (Figure 2).
The objectives of this conference were to arrive at a
consensus among five organizations dedicated to vascular
disease and its complications and to develop a common
agenda and strategies for global prevention of chronic
vascular diseases, particularly in the developing world. The
participating organizations, which are already involved in
advocacy and/or prevention programs, believe that their
overlapping science, such as risk factors, makes collaboration
both practical and beneficial.
GLOBAL PERSPECTIVE ON DIABETES AND CARDIOVASCULAR
AND RENAL DISEASE
Dirks (Canada) began with an overview on chronic diseases.
In 2005, they caused over 35 million or 60% of all deaths
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worldwide. With the exception of sub-Saharan Africa, they
have surpassed infectious diseases as the major cause of
morbidity and mortality, the majority due to diseases
affecting the vascular system.
Contrary to popular mythology, these diseases are not the
revenge of the human body on a wealthy and overindulgent
lifestyle, nor are they diseases of old age. Almost 80% of the
deaths from chronic disease occur in countries with
developing economies and half of them occur in people
under 70 years of age.1 Poor people have fewer choices
regarding diet, living conditions, and access to education and
health care. It is estimated that between 1990 and 2020,
annual mortality rates from cardiovascular disease (CVD)
alone will more than double within countries with develop-
ing economies.2 Economic considerations alone would seem
to make prevention an obvious approach to the growing
prevalence of chronic diseases.
Unwin (UK) gave the WHO perspective, pointing out
that health-care models in nearly all countries allocate
virtually all their health-care dollars to treatment and
very little to prevention. In the US, the ratio is 95% to 5%.
The same lack of focus on prevention exists in emerging
nations: in 2002, although development aid to the health
sector was $2.9 (US) billion, a scant 0.1% went to chronic
diseases.3 WHO spent 3.5% of its 2002 budget on chronic
diseases. It estimates that 80% of heart disease, stroke and
diabetes could be prevented if the known risk factors were
eliminated. Most importantly, this need not be a costly
undertaking.
Jamison (US) attributed 10–15% of the economic growth
in developing countries to improvements in population
health.4 The increase in the prevalence of chronic diseases,
however, is a growing threat to their economies. The
Developing Countries Priorities Project, second edition
estimates the cost effectiveness and impact of single and
multiple interventions. An analysis of the disease burden in
selected low- and middle-income countries showed that CVD
and stroke ranked second and fourth among all diseases in
terms of disability-adjusted life years.5 The study compared
the efficacy (disability-adjusted life years averted) of taxation
of tobacco products versus various treatment interventions
and found that taxation would be the most effective single
undertaking, and at the least cost.
Alderman (USA) pointed out that hypertension now
affects 26% of the world’s population6 and is increasing.
Although rates are expected by 2025 to increase by just over
28% in developed countries, they will almost double in the
Middle East and sub-Saharan Africa, and increase substan-
tially in India, Latin America, and South East Asia.
Furthermore, although treatment is both efficacious and
available, control levels remain stubbornly low, ranging
from about 6 to 27% in the developed world.7 He reported
that currently 68% of disability-adjusted life years
attributable to non-optimal blood pressure occur in develop-
ing countries, and 43% in people 30–59 years of age. Studies
have shown that the risk of cardiovascular (CV) events is
linear from a systolic reading of 115 mm Hg,
which suggests that the current definition of hypertension
may not be useful because risk levels of blood pressure are
continuous.
Smith (USA) confirmed that coronary heart disease is now
the leading cause of mortality in every area of the world
except sub-Saharan Africa. In the developing world, there is a
correlation between urbanization and the increase in
coronary heart disease. In addition, tobacco use has
surpassed human immunodeficiency virus and diarrheal
diseases as a major cause of death. To assist efforts to prevent
CVD in developing countries, the World Heart Federation
has published principles8 for national and regional guidelines
on CVD prevention, indicating that strategies should be
Figure 1 | Five international organizations brought together
representatives from the developing and the developed world
in Bellagio, Italy to discuss an integrated approach to global
prevention of chronic vascular diseases.
Figure 2 | After 3 days of intensive talks, the group resolved to
work toward developing a consortium of six organizations and
the establishment of a 5-year plan for the prevention and
treatment of chronic vascular diseases.
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based on epidemiologic risk factor data appropriate to the
population to which it is applied.
Remuzzi (Italy) described an array of ISN-supported
screening and interventional studies in developing countries.
Investigators are trained in a Western country, and upon
returning home lead the local study in tandem with their
Western partners, resulting in significant capacity building in
nephrology epidemiology. He has concluded that research
capacity in vascular disease should be coordinated so that
various specialists work together. Centers of excellence in
selected sites in the developing world, linked with developed
centers, could advance international vascular research.
Remuzzi estimates that there are 60 million individuals
worldwide with early kidney disease to end-stage renal
disease. However, after a 20-year increase, kidney disease in
the USA has begun to level off as a result of improved clinical
strategies including increased prescription of angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers.
Unwin showed that diabetes is increasing most in
developing countries. Seven of the top 10 countries whose
35- to 64-year-old population suffers from the disease are in
the low- and middle-income group (i.e. Brazil, India,
Indonesia). By 2030, WHO estimates that 366 million people
will have diabetes, overwhelmingly Type II. Of these, up to
40% will develop diabetic nephropathy, 25% visual impair-
ment, 33% peripheral neuropathy, and 66% will die of CVD.
An estimated 2.9 million people aged 35–64 died from
diabetes in 2000.9 Although there is a lack of data from many
countries, WHO estimates that diabetes accounts for 2.5–15%
of national health-care budgets. In many, diabetes can be
delayed or prevented through weight loss, diet adjustment,
and increased physical activity as shown in the Finnish
diabetes prevention study, which resulted in a 50% reduction
in the control group.10
Nine recognized risk factors account for 90% of CV events:
hypertension, smoking, abdominal obesity, physical inacti-
vity, APoB/APoA, diabetes, psychosocial factors, insufficient
fruit and vegetables, and alcohol. Metabolic syndrome,
prevalent in all countries, has been identified as a multi-
dimensional risk factor for CVD (Grundy, USA). It increases
with abdominal obesity but it is unclear whether this or
insulin resistance is its underlying cause. It leads to increased
risk of diabetes mellitus (five-fold) and CVD (1.5- to three-
fold), with greater risk for South Asians.
Yusuf ’s 52 country Interheart Study11 has established
waist-to-hip ratio as a better indicator for acute myocardial
infarction risk than body mass index (BMI) categories. This
is true of all ethnic groups, leading him to believe ethnicity is
a better marker of lifestyle differences than genetic differ-
ences. He questions the descriptive categories of BMI,
pointing out that there are probably no healthy adults in
North America with a BMI of p20. This leads to the
question, What is normal? His study indicated that within a
given population, obesity accounts for 34% of the risk for
acute myocardial infarction, which in developed countries is
higher than smoking.
CVD IN THE DEVELOPING WORLD: WHY THE NEED FOR
PREVENTION?
Reddy (India) focused on the role of socio-economic
gradients in the risk factors for CVD using as examples
India and China. A study within 10 industries in India
showed a direct correlation between educational status and
five risk factors for CVD, namely smoking, regular physical
activity, diabetes, hypertension, and metabolic syndrome. In
four educational groups (post-graduate, graduate, high
school, primary/illiterate), the five risk factors were inversely
related to the levels of education.12 In China, where acute
coronary events increased between 1984 and 1997 at a rate of
1.7% a year, a study on women aged 15–69 years at three
different educational levels yielded similar results.13
Rodriguez-Iturbe (Venezuela) reported that there is
significant disagreement in reported studies about the
prevalence, treatment, and control of hypertension in Latin
America. Variable diagnostic criteria are used and data
sampling techniques are not always consistent.14 In some
countries, there are no statistics available on prevalence,
treatment, or control.
Forrester’s (Jamaica) presentation on the African Ameri-
can Diaspora Study, the International Collaborative Study on
Hypertension in Blacks, compared 9577 black adults in four
West African sites, three Caribbean sites, and one American
site for prevalence of hypertension.15 He found that
prevalence of hypertension increased with per capita GNP,
from 16% in West Africa to 26% in the Caribbean to 33% in
the USA. Environmental factors, specifically obesity, and
sodium and potassium intake vary with the prevalence of
hypertension.
Tobacco is the second leading cause of mortality world-
wide and its use remains high in the developing world. In
China 70% smoke, and in Indonesia 60% use tobacco,
including 16% of children 13–15 years old. Zaman (Bangla-
desh) demonstrated the high opportunity costs for the
population (50%) that uses tobacco. When the revenue from
taxes and tobacco-related employment are set off against
direct and indirect medical costs, tobacco costs the country
US $44 million per year.16
Smoking cessation provides the best example of how
effective a concerted national program of education and
prevention can be in changing behaviors. In developed
countries where such programs have been in effect for over 20
years, smoking rates have dropped significantly through a
combination of media campaigns, smoking restrictions,
advertising bans, and increased taxes. The tax increase has
been particularly effective among teenagers, a price-sensitive
group, as would presumably be the case within other low-
income populations.
PREVENTION OF KIDNEY DISEASE AND DIABETES IN
DEVELOPING COUNTRIES
One of the more animated discussions took place over de
Zeeuw’s (The Netherlands) presentation on albuminuria as a
marker for CVD and kidney disease. According to his
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RENAAL study, the more the albuminuria in the urine, the
more the risk for chronic kidney disease (CKD), CVD, and
diabetes. In the IRMA study,17 reducing proteinuria through
treatment with sartans achieved a risk reduction of 70% for
diabetic nephropathy. The PRIME study showed that earlier
interventions are better. In controlled studies in the USA and
Groningen (The Netherlands), mild renal dysfunction
(albuminuria plus decreased glomerular filtration rate were
found in 11 and 10.5%, respectively. In several studies,
microalbumninuria was found in 5–7% of the ‘healthy’
population, 20–30% of the hypertensive population, and up
to 40% of diabetics.
In the PREVEND study, albuminuria was found to predict
moderate (Stage 3) CKD.18 Preliminary data from the same
study showed that high albuminuria concentrations could be
a better predicator of CV mortality than hypertension.19
Treatment of albuminuria with angiotensin-converting en-
zyme inhibitors showed a risk reduction for CV mortality of
40–44% over 40 months,20 a cost-effective treatment.
Discussion indicated that cardiologists remain uncertain
about the additive value of microalbuminuria to standard CV
risk factors, and questions remain to be answered about the
pathogenic process by which protein leakage affects the
vascular system. De Zeeuw called for a working party from
the participating societies to standardize the measurement
and definition of albuminuria, and its use in CVD and CKD
assessment.
In Africa, intervention to prevent or slow kidney disease is
the only economically viable approach, according to Naicker
(South Africa). A survey of 16 Sub-Saharan African countries
indicates the prevalence of end-stage renal disease from a
high of 75.5 patients per million of population in South
Africa to a low of 1.6 in Ghana. There is a correlation in most
developing countries between average income and rates of
reported end-stage renal disease, suggesting that the varia-
bility has more to do with economics than true prevalence.
There is a shortage of general physicians as indicated by a
WHO survey of 27 African countries indicating that 17
countries have fewer than nine physicians per 100 000 people.
Ghana, Togo, and Zambia have only two nephrologists and
two dialysis units each. Where available, dialysis is usually
unaffordable. For instance, in Nigeria, Ghana, Senegal, and
Togo, it costs $100 per dialysis, more than in most developed
countries and far more than the average monthly income of
most Africans. Latin America (Rodriguez-Iturbe) shares
many issues with Africa, to a lesser degree. With the
exception of Uruguay, Chile, Costa Rica, and Mexico, CKD
is both underreported and undertreated. Diabetic nephro-
pathy and hypertension are the main causes of CKD,
reflecting a more ‘Western’ profile.
An ISN early detection and intervention program in
Morocco (de Broe) will identify at-risk patients through
community-wide (100 000 people in two communities)
screening programs. It will examine the role of occupational
exposure and traditional medicines in the development of
CKD. The protocol is based on the ISN ‘Program for
detection and management of chronic kidney disease,
hypertension, diabetes and cardiovascular disease in develop-
ing countries’, a flexible model applicable according to local
conditions.
In India’s rapidly growing cities, diabetes rates are double
the USA rates. Ramachandran’s (India) study showed that
both the age and the BMI threshold for diabetes are lower in
Indians (23) compared to Europeans (27.5). Another
observed characteristic is that Indians have higher central
obesity and fat mass for a given BMI. It is speculated that this
results in high rates of insulin resistance (16.8% in 2000).
A control trial on primary prevention of diabetes on
subjects with impaired glucose tolerance found that the
conversion rate of impaired glucose tolerance to diabetes is
high (55% in 3 years). Conversion rates were reduced by
28.5% using lifestyle modifications other than weight loss,
and by 26.4% using metformin. There was no added benefit
to using both.21
Ramaiya (Tanzania) reported that in Africa, diabetes
medications are often unavailable and usually unaffordable.
The complications of diabetes are high; ketoacidosis is
common and contributes to the high mortality (25% in
Tanzania, 33% in Kenya). Retinopathy is also high (21–25%
of Type II patients in South Africa); 35% of all dialysis
patients have diabetes; and 40–60% of non-traumatic
amputations are diabetes related.
A study by Cardoso (Brazil) of 471 Type II diabetics of
Japanese descent over a 5-year period in Brazil reported 121
deaths over 5 years, 36% from CVD and 33% from
infection.22 We conclude that both prevention and treatment
of diabetes is a worldwide problem.
A GLOBAL IMPLEMENTATION PLAN FOR
NON-COMMUNICABLE DISEASES
Unwin presented the WHO plan for reducing the chronic
disease burden by 2% annually over the next decade. Nine of
10 lives saved would be in low- and middle-income countries,
resulting in massive savings: over $35 billion in China, nearly
$20 billion in Russia, and almost $15 billion in India. The
WHO Stepwise framework involves a comprehensive and
integrated action plan, including (1) estimating the popula-
tion need and advocating for action, (2) formulating and
adopting prevention and control policies, and (3) identifying
the policy implementation steps at the national, sub-national,
and individual level. It begins with interventions using
existing resources, proceeds to interventions with realistically
increased resources, and finally moves to evidence-based
interventions beyond the reach of current resources.
Jamison described the mission of the Ellison Institute
(Harvard), to improve population health and the efficiency of
health system resources. It will seek out and make available
credible, comprehensible, and comparable information where
it is lacking. Partnerships with 15–20 low-, middle-, and high-
income countries will be established to undertake capacity
building to match the analytical agenda in each one. Potential
areas of activity include health intervention delivery, burden
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of disease and comparative risk assessment, population
health, system efficiency, and policy analysis.
Alderman said that lack of research within the emerging
world is a major problem, exemplified by the fact that 82 of
192 countries published nothing on CVD in major interna-
tional peer-reviewed journals between 1991 and 2001.23 Over
half the International Medical Graduates in North America,
the UK, and Australia come from developing countries. This
brain drain has had a negative effect not only on patient care
but also on the establishment of role models, mentorship and
training programs, and research capacity.
Yusuf described international research being undertaken
by the Population and Health Research Institute (Hamilton,
Canada). It has undertaken a number of global epidemiolo-
gical studies including the Interheart Study (on risk factors
for acute myocardial infarction) on 30 000 people in 52 low-,
middle-, and high-income countries, and the PURE (pro-
spective urban rural epidemiologic) study, which looked at
the impact of risk factor modification on myocardial
infarction in 135 000 people in 15 low-, middle-, and high-
income countries.
He described the problems of conducting research in low-
and middle-income countries – limited funds, lack of
recognition of chronic diseases, personnel shortages, few
role models, and a limited culture of research. The practical
challenges of such research include regulatory difficulties,
lack of local expertise and equipment, the integrity of drugs
and blood, and maintaining long-term follow-up. However,
he stressed the positive advantages to locals who are trained
by being involved in his projects. Local principal investigators
who are knowledgeable about research and local issues are
needed. Yusuf iterated that international research has
scientific, cultural, political, and health benefits for develop-
ing countries and benefits developed countries by providing
understanding of the evolution of chronic disease.
A program called Heartfile has been developed by Nishtar
(Pakistan). Its purpose is to improve CV outcomes in less
well-resources settings. Heartfile has laid out an economically
and socially viable blueprint for health systems and
community demonstration projects generating the evidence
for advocacy and advocacy for chronic diseases.
Steyn (South Africa) pointed out that AIDs care is forcing
poor countries to develop models for chronic disease care,
which provides an opportunity to links that care for all
patients with chronic conditions.
THE CHALLENGE OF DEALING WITH CHRONIC DISEASE
Falling death rates for CVD in developed countries over the
last 30 years suggest that with an effective, well-funded action
plan, large improvements can be made in developing countries.
Remuzzi established the correlation between poor health
and poverty. Several speakers (Unwin, Zhao, Jamison)
referred to the threat that chronic diseases cause to economic
development through projected foregone national income. In
China, WHO estimates US$550 billion will be lost as a result
of diabetes, heart disease, and stroke between 2005 and 2105.
Although few emerging countries have the resources to deal
with chronic disease, the large international agencies have
concentrated solely on communicable diseases. Over the past
5 years, the World Bank has provided US$4.25 billion in
loans to countries for health sector work, but only US$106
million to non-communicable disease prevention and control
programs.24
With the exception of tobacco control, WHO spends 1/15
as much on chronic diseases as on communicable diseases in
spite of its own Commission on Macroeconomics and Health
(WHO, 1999) which recommended that developed countries
should quadruple their donations to developing countries for
health promotion.
An international strategy including governments, inter-
national agencies, international scientific societies, academic
centers, foundations, and pharmaceutical companies is
required. Remuzzi pointed out that the latter are the most
profitable economic sector (18.6% as compared to 11.7% for
telecommunications, the next highest)25 led by drugs for
chronic vascular diseases. Given that they are not included in
the Millennium Development Goals, Remuzzi urged the
creation of a Global Fund to fight chronic diseases. Such a
fund must be used to activate or implement prevention/
education programs and increase capacity, particularly at the
primary care level. Remuzzi suggested that creating centers of
excellence within emerging countries would be an appro-
priate approach.
Paehler described the research and policy direction for
chronic diseases announced by the European Commission,26
which has established health as one of nine thematic
priorities. The three pillars underlying their program include
(a) biotechnology, generic tools and technologies for human
health, (b) translating research for human health, and (c)
optimizing delivery of health care to European citizens.
Bengoa (WHO) said, ‘Let’s get beyond the documentation
of the chronic disease burden. It’s insufficient to bring about
change’. He presented on the need for refined health-care
systems that will respond better to chronic disease by
intervening across the entire disease continuum, bringing
together public and clinical perspectives and implementing
evidence-based models of care (i.e. connect broader popula-
tion upstream intervention (primary and secondary care) on
populations with downstream intervention on individuals).27
The system must treat the patient continuously and not
sporadically. A study on shortfalls in care for diabetes (blood
sugar not normalized for 24%) showed 26 000 going blind
and 29 000 with kidney failure. Similarly, in hypertensive
patients (where less than 65% received appropriate care), the
toll was 68 000 deaths.28
Where there are health-care providers with defined goals,
outcomes appear to be improved. An excellent example is the
Washington State Collaboratives.29
Bengoa concluded by stressing sharper asset planning to
build an integrated system for diabetes, CVD, and kidney
disease. The skill is to take the coalition of special societies
and work out a single system for chronic vascular care.
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Advocacy and awareness building are necessary precursors
to any program for prevention, particularly in developing
countries. International medical societies are uniquely
positioned to play an effective role because of their global
membership networks, international partnerships, screening
and intervention studies, establishment of practice guidelines,
and their long-term commitments within the developing
world. ISN (Couser) with over 8000 members is affiliated
with 70 national societies; World Heart Federation’s network
involves 186 national society and foundation members in 100
countries; International Society of Hypertension has 800
members in 64 countries; International Diabetes Federation
is an umbrella organization of over 190 diabetes organiza-
tions; and International Atherosclerosis Society has 55
member societies worldwide.
CONCLUSION
The focus of the Bellagio meeting was encapsulated by two
questions posed during its very first session: (1) why are we
not moving towards more assistance for chronic diseases, and
what can this group do about it; and (2) what is the right
policy response to increasing numbers of people needing
treatment for chronic diseases? (This meeting created a
platform for a more integrated approach to vascular diseases.
The participants resolved to work jointly and to collaborate
on developing a 5-year plan to increase prevention activities
including formal goals, a strategy, and a time line with
milestones to assess progress. Stroke-associated societies
should also be included.
There was a clear consensus that chronic diseases have
been underfunded by international agencies and have lacked
advocates to bring them to the world’s attention. Yusuf said
the mindset to date, which must be changed, has been to
fund either chronic diseases or communicable diseases but
not both. Furthermore, all agreed that tackling the risk
factors rather than the diseases themselves would yield better
results. The meeting ended on a note of high optimism that
such an approach can be effective when a number of
organizations collaborate to work towards an integrated
approach to chronic vascular diseases.
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